Proteasome inhibitor MG132, histone deacetylase (HDAC) inhibitor NaBu, p300 inhibitor C646 and A485, Src inhibitor were purchased from MCE company (NJ, USA). Cycloheximide (CHX) was purchased from Sigma-Aldrich (St. Louis, MO, USA). The siRNAs targeting indicated genes were conducted by Gemepharma Company (Shanghai, China).

The expression vectors containing the p300, c-Jun, COL6A1, SOCS5, mutant SOCS5, HA-tagged Wild type (wt) Ubiqution (Ub), HA-tagged K11R Ub, HA-tagged K48R Ub and HA-tagged K63R Ub plasmids were purchased from Vigene (Shanghai, China). GFP-tagged wild type STAT1 (wt), GFP-tagged STAT1 (Y701A), and GFP-tagged STAT1 (S727A) were purchased from Addgene (Watertown, MA, USA).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.